# OnCo record nct02332668 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02332668/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02332668", "NCT02332668" ;
  schema:name "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)"@en ;
  schema:alternateName "KEYNOTE-051"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab in melanoma and hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02332668/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02332668> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2015-03-19" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct02332668-lancet-oncol-2020/> .